Ferumoxytol
- Generic Name
- Ferumoxytol
- Brand Names
- Feraheme
- Drug Type
- Small Molecule
- Chemical Formula
- Fe3O4
- CAS Number
- 722492-56-0
- Unique Ingredient Identifier
- G6N3J05W84
- Background
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
...
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) .
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01264679
- Locations
- 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 296
- Registration Number
- NCT01227616
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Montréal, Canada
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01155388
- Locations
- 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01155375
- Locations
- 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
Iron Indices and Intravenous Ferumoxytol: Time to Steady State
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Dialysis Clinic, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01148745
- Locations
- 🇺🇸
Dialysis Clinic, Inc., North Brunswick, New Jersey, United States
A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 605
- Registration Number
- NCT01114204
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
🇱🇻For additional this triinformation regarding investigative sites for al, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riga, Latvia
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 634
- Registration Number
- NCT01114217
- Locations
- 🇵🇱
Clinical Trial Site, Wrocław, Poland
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 812
- Registration Number
- NCT01114139
- Locations
- 🇺🇸
AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, United States
🇵🇱Clinical Trial Site, Zgierz, Poland
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT01052779
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montréal, Quebec, Canada
🇬🇧For additional information regarding investigative sites for this trial, contact 1-617-498-3300 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00978562
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.